Novitium launches generic Revatio
Novitium Pharma has received the Food and Drug Administration’s clearance for its generic Revatio (sildenafil for oral suspension, 10mg/mL). The company said it already has begun launching the product.
“We are pleased to announce that the launch of sildenafil for oral suspension has already initiated,” Novitium CEO Chad Gassert said. “Novitium remains dedicated to providing patients with a steady supply of affordable treatment options, and to progressing the availability of generics in niche therapeutic categories.”
Revatio for oral suspension, 10mg/ml had a market value of about $200 million for the 12 months ending March 2019, according to IQVIA.
“We are pleased to announce that the launch of sildenafil for oral suspension has already initiated,” Novitium CEO Chad Gassert said. “Novitium remains dedicated to providing patients with a steady supply of affordable treatment options, and to progressing the availability of generics in niche therapeutic categories.”
Revatio for oral suspension, 10mg/ml had a market value of about $200 million for the 12 months ending March 2019, according to IQVIA.